PHR SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Phreesia, Inc. Investors - Contact Kirby McInerney LLP by July 13, 2026
Kirby McInerney LLP reminds investors who purchased Phreesia, Inc. (NYSE:PHR) securities to contact the firm regarding a securities fraud class action lawsuit. Investors have until July 13, 2026, to request lead plaintiff appointment. The lawsuit alleges that Phreesia made misleading statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.
Securities Fraud Investigation Into Phreesia Inc. (PHR) Announced
The Law Offices of Frank R. Cruz have announced a securities fraud investigation into Phreesia Inc. (PHR) following a significant drop in its stock price. This inquiry comes after Phreesia announced lowered revenue growth projections for fiscal 2027 on March 30, 2026, attributing it to macroeconomic factors and weaker pharmaceutical marketing commitments, which caused its stock to fall by 26.6%. The firm is urging investors who lost money to contact them regarding potential claims.
PHR Shareholder Alert: Phreesia, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
SueWallSt has notified investors that a class action lawsuit has been filed against Phreesia, Inc. (NYSE: PHR) on behalf of shareholders who purchased securities between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia's leadership withheld information about weakening pharmaceutical marketing commitments, leading to a 27% stock price decline after the company disclosed lower-than-anticipated commitments for fiscal 2027. Investors affected during the class period are encouraged to contact SueWallSt to recover potential losses before the lead plaintiff deadline of July 13, 2026.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit
The Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made false and misleading statements regarding its demand and reduced visibility in key revenue streams. Investors who suffered damages are encouraged to join the class action, with a deadline of July 13, 2026, to move for lead plaintiff status.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit
The Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made misleading statements regarding slowing demand and reduced visibility in key revenue streams. Investors who suffered damages during this period have until July 13, 2026, to move the Court to serve as lead plaintiff.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before ...
Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Phreesia, Inc. (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made false or misleading statements and concealed adverse facts about its slowing demand and reduced visibility in key revenue streams. Investors have until July 13, 2026, to move the Court to serve as lead plaintiff.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is announcing a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made misleading statements regarding slowing demand and reduced visibility in key revenue streams. Investors who suffered damages are encouraged to join the class action by July 13, 2026, to potentially serve as lead plaintiff.
Phreesia (PHR) accounting officer sells 431 shares under 10b5-1 plan
Phreesia, Inc.'s Principal Accounting Officer, Yvonne Hui, reported an insider transaction involving the sale of 431 shares of common stock at $8.85 per share under a pre-arranged Rule 10b5-1 trading plan. Additionally, 325 shares were withheld to cover tax obligations related to the settlement of restricted stock units, which is noted as not being a discretionary sale. Following these transactions, Hui beneficially owns 24,233 shares of common stock.
PHR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE:PHR) and certain officers. The lawsuit alleges that Phreesia made false and misleading statements about slowing demand and weakened pharmaceutical marketing commitments, leading to substantial losses for investors who purchased shares between May 8, 2025, and March 30, 2026. Investors with losses are encouraged to join the lawsuit and have until July 13, 2026, to request to be appointed lead plaintiff.
Portnoy Law Firm Announces Class Action on Behalf of Phreesia, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased securities between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia failed to disclose weakening pharmaceutical marketing commitments and reduced visibility into future spending, leading to a significant drop in its stock price after a lowered fiscal year 2027 revenue outlook was announced. Investors have until July 13, 2026, to file a lead plaintiff motion.
PHR DEADLINE: Levi & Korsinsky Reminds Phreesia, Inc. Investors of Upcoming Securities Class Action Deadline
Levi & Korsinsky, LLP is reminding investors of Phreesia, Inc. (NYSE: PHR) about an upcoming securities class action deadline, July 13, 2026, for investors who purchased shares between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors about its growth durability and the contributions from its AccessOne acquisition, even as pharmaceutical marketing commitments were weakening. Phreesia later slashed its fiscal 2027 revenue outlook, leading to a significant stock price decline.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors who purchased Phreesia, Inc. (NYSE: PHR) securities between May 8, 2025, and March 30, 2026, to join a class action lawsuit. The lawsuit alleges that Phreesia made false and misleading statements regarding its long-term growth outlook and confidence in fiscal year 2027 projections, particularly concerning pharmaceutical marketing commitments. Shareholders who suffered losses are urged to contact the firm before July 13, 2026, to discuss their rights.
PHR Shareholder Alert: July 13, 2026 Lead Plaintiff Deadline in Phreesia, Inc. Securities Class Action - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Phreesia, Inc. (NYSE: PHR), announcing a lead plaintiff deadline of July 13, 2026, for a securities class action lawsuit. The lawsuit alleges that Phreesia made false and misleading statements regarding its slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. This follows a significant drop in stock price after the company announced reduced revenue growth projections in March 2026.
PHR Class Action Notice: Robbins LLP Reminds Investors of
Robbins LLP is reminding investors of a class action lawsuit filed against Phreesia, Inc. (NYSE: PHR) for alleged misleading statements regarding the sustainability of growth in its Network Solutions business and its fiscal year 2027 revenue outlook. The lawsuit claims Phreesia failed to disclose weakening pharmaceutical marketing commitments and reduced visibility into future spending, leading to a significant stock price drop. Investors who purchased shares between May 8, 2025, and March 30, 2026, have until July 13, 2026, to submit their papers to serve as lead plaintiff.
PHR (PHR) restricted stock vests; Yvonne Hui sold 11,390 shares
A Rule 144 notice filed by PHR (Phreesia, Inc.) reports restricted stock vesting on May 15, 2026, and the subsequent sale of 11,390 shares by Yvonne Hui in two separate transactions on April 16 and April 17, 2026. The filing is administrative, detailing compensation-related vesting and subsequent dispositions without specifying cash flow details or implying new issuance. It serves to inform the market about stock becoming tradable under Rule 144 regulations.
PHR Shareholder Alert: Phreesia, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased securities between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors by overstating fiscal 2027 revenue projections, which were later significantly cut, causing a 27% stock drop. Investors with losses are encouraged to contact the law firm, with a lead plaintiff deadline of July 13, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Phreesia, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased securities between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made false and misleading statements regarding slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who suffered losses are encouraged to contact the firm by July 13, 2026, to request lead plaintiff appointment.
Bronstein, Gewirtz & Grossman LLC Urges Phreesia, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) and its officers. The lawsuit alleges that Phreesia made false and misleading statements regarding slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments between May 8, 2025, and March 30, 2026. Investors who purchased Phreesia securities during this period are encouraged to join the class action by July 13, 2026, to potentially recover damages.
Bronstein, Gewirtz & Grossman LLC Urges Phreesia, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased securities between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made misleading statements regarding slowing demand, diminished revenue visibility, and weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who suffered losses are encouraged to join the case by July 13, 2026, and the firm operates on a contingency fee basis.
Bronstein, Gewirtz & Grossman LLC Urges Phreesia, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) and its officers, alleging violations of federal securities laws. The lawsuit claims that Phreesia made false and misleading statements regarding slowing demand, diminished revenue streams, and weakened pharmaceutical marketing commitments between May 8, 2025, and March 30, 2026. Investors who purchased Phreesia securities during this period are encouraged to join the case, with a lead plaintiff deadline of July 13, 2026.
Pomerantz LLP Advises Shareholders of Class Action Involving Phreesia, Inc. – PHR
Pomerantz LLP has announced a class action lawsuit filed against Phreesia, Inc. (NYSE: PHR) following a significant reduction in the company's revenue growth projections for fiscal year 2027. Shareholders who purchased Phreesia securities during the Class Period are advised to contact the firm, with a deadline of July 13, 2026, to seek appointment as Lead Plaintiff. The lawsuit alleges securities fraud or other unlawful business practices after Phreesia's stock price fell 26.56% on March 31, 2026, due to worsening visibility and weaker pharmaceutical marketing commitments.
INVESTOR ALERT: Securities Class Action Filed Against Phreesia, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) for alleged materially false and misleading statements made to investors between May 8, 2025, and March 30, 2026. The lawsuit claims the Company concealed slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments, leading to a significant stock price decline. Investors who suffered losses are encouraged to contact Kirby McInerney LLP to potentially serve as lead plaintiff by the July 13, 2026 deadline.
INVESTOR ALERT: Securities Class Action Filed Against Phreesia, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) on behalf of investors who purchased securities between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Investors who suffered losses are encouraged to contact Kirby McInerney LLP by July 13, 2026, to request lead plaintiff appointment.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Phreesia, Inc. (NYSE: PHR) for alleged securities fraud. The lawsuit claims Phreesia made false and misleading statements regarding its long-term growth outlook and fiscal year 2027 projections, particularly concerning the Network Solutions segment. Investors who purchased securities between May 8, 2025, and March 30, 2026, are encouraged to contact the firm before July 13, 2026, to participate.
Phreesia (PHR) Downgraded by Barclays Amid Slowing Digital Growt
Barclays has downgraded Phreesia (PHR) from Overweight to Equal Weight and reduced its price target from $24 to $10, citing concerns about slowing growth in digital advertising and increased competition. The company's high P/E ratio of 292.33x suggests potential overvaluation, further supported by significant insider selling activities. While Phreesia has a moderate GF Score™ of 62, its low profitability and financial strength ranks indicate challenges ahead.
Phreesia, Inc. ($PHR) CEO 2026 Pay Revealed
Phreesia, Inc.'s CEO, Chaim Indig, is estimated to receive $8,077,706 in compensation for 2026, a 30.12% decrease from 2025. This compensation data comes from a recent SEC filing. The article also provides details on insider trading, congressional stock trading, hedge fund activity, analyst ratings, and price targets for $PHR.
PHR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against Phreesia, Inc.
Robbins LLP, a shareholder rights law firm, has filed a class action lawsuit on behalf of investors who purchased Phreesia, Inc. (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors by failing to disclose weakening pharmaceutical marketing commitments within its Network Solutions segment and reduced visibility into future spending, which put its fiscal year 2027 revenue guidance at risk. Following the announcement of a lowered revenue outlook, Phreesia's stock price dropped by approximately 27%.
Rosen Law Firm Urges Phreesia, Inc. (NYSE: PHR) Stockholders to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors by concealing slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Shareholders are encouraged to contact the firm by July 13, 2026, to potentially serve as lead plaintiff.
Phreesia (PHR) 2026 proxy details board refresh, virtual meeting and say-on-pay
Phreesia (PHR) has released its 2026 proxy statement, detailing plans for its upcoming virtual annual meeting on June 24, 2026, where shareholders will vote on director elections, auditor ratification, and executive compensation. The board will be refreshed, reducing from nine to seven members, with independent director Ramin Sayar taking over as Chair. The statement also highlights the company's commitment to strong corporate governance, including a highly independent and diverse board, and provides details on executive and non-employee director compensation policies aligned with performance and shareholder interests.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit
The Rosen Law Firm announces a class action lawsuit on behalf of investors who purchased Phreesia, Inc. (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026. Investors have until July 13, 2026, to move the Court to serve as lead plaintiff. The lawsuit alleges that Phreesia made false or misleading statements regarding its slowing demand and reduced visibility in key revenue streams due to weakened pharmaceutical marketing commitments.
Rosen Law Firm Urges Phreesia, Inc. (NYSE: PHR) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made misleading statements and concealed material facts regarding slowing demand and reduced visibility in key revenue streams. Shareholders are urged to contact the firm by July 13, 2026, to discuss serving as lead plaintiff.
PHR Investors Have Opportunity to Lead Phreesia, Inc. Securities Fraud Lawsuit
The Rosen Law Firm has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made false and misleading statements regarding its slowing demand and reduced visibility in key revenue streams, specifically weakened pharmaceutical marketing commitments. Investors who wish to serve as lead plaintiff must do so by July 13, 2026.
PHR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Deadline on July 13, 2026
Faruqi & Faruqi, LLP is reminding investors of the July 13, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit against Phreesia, Inc. The lawsuit alleges that Phreesia made misleading statements and failed to disclose slowing demand and reduced visibility in key revenue streams, specifically in its Network Solutions segment. This follows a significant drop in Phreesia's stock price after the company reduced its fiscal year 2027 revenue guidance due to weakness in pharmaceutical marketing.
PHR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Deadline on July 13, 2026
Faruqi & Faruqi, LLP is investigating potential claims against Phreesia, Inc. (NYSE: PHR) and reminds investors of the July 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Phreesia and its executives made misleading statements regarding slowing demand and reduced visibility in its Network Solutions segment, specifically concerning pharmaceutical marketing commitments. This announcement follows a significant stock price drop after Phreesia reduced its revenue guidance for fiscal year 2027.
Investor Notice: Robbins LLP Informs Investors of the Phreesia, Inc. Class Action
Robbins LLP has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors regarding the sustainability of growth in its Network Solutions segment and its fiscal year 2026 revenue outlook. This comes after the Company lowered its fiscal year 2026 revenue outlook and experienced a significant stock price drop.
Investor Notice: Robbins LLP Informs Investors of the Phreesia, Inc. Class Action
Robbins LLP has filed a class action lawsuit against Phreesia, Inc. on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors about the sustainability of growth in its Network Solutions business and its fiscal year 2027 revenue outlook. This announcement follows a significant drop in Phreesia's stock price after the company lowered its fiscal year 2027 revenue guidance due to weakening pharmaceutical marketing commitments and reduced visibility into future spending.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Phreesia, Inc. Common Stock and Sets a Lead Plaintiff Deadline of July 13, 2026
Levi & Korsinsky, LLP has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased common stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia made misleading statements about its slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Following a significant reduction in revenue growth projections, Phreesia's stock price declined by approximately 27%, and investors have until July 13, 2026, to request to be appointed as lead plaintiff.
Investor Notice: Robbins LLP Informs Investors of the Phreesia, Inc. Class Action
Robbins LLP has announced a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors by failing to disclose weakening pharmaceutical marketing commitments, reduced visibility into future spending, and increased variability in its Network Solutions revenue forecasting, which put its fiscal year 2027 revenue guidance at risk. This alleged misinformation led to a significant drop in Phreesia's stock price after the company lowered its fiscal year 2027 revenue outlook.
Phreesia Sets May 27 Date for Quarterly Results
Phreesia, Inc. (NYSE: PHR) announced it will release its fiscal first-quarter 2027 financial results after markets close on May 27, followed by a conference call at 5 p.m. Eastern Time. The company will post quarterly results and a stakeholder letter on its investor relations website, and investors can access the conference call via phone or webcast. Phreesia develops patient engagement and healthcare intake technology and actively supports local news in Chester County.
Investor Notice: Robbins LLP Informs Investors of the Phreesia, Inc. Class Action
Robbins LLP has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) on behalf of investors who purchased stock between May 8, 2025, and March 30, 2026. The lawsuit alleges that Phreesia misled investors about the sustainability of its Network Solutions business growth and fiscal year 2027 revenue outlook. This announcement follows a 27% drop in Phreesia's stock price after the company lowered its fiscal year 2027 revenue outlook, citing weakening pharmaceutical marketing commitments and reduced visibility into future spending.
Job cuts at Phreesia (NYSE: PHR) as restructuring targets 220 roles
Phreesia, Inc. has initiated a restructuring plan to reduce operating expenses and align its cost structure with current business priorities, involving the elimination of approximately 220 positions, about half of which are contractor roles. The company anticipates non-material restructuring costs, mostly in fiscal year 2027, and expects meaningful annualized run-rate expense savings. These savings were already factored into its Adjusted EBITDA outlook for fiscal year 2027, indicating the plan is an execution of an existing profitability strategy rather than a change in targets.
Phreesia Reports New $275 Million Revolving Credit Facility
Phreesia has announced a new $275 million revolving credit facility, which replaces its previous $125 million facility. This new agreement enhances the company's financial flexibility, extends its debt maturity profile to 2029, and significantly reduces its borrowing costs, demonstrating strong support from its banking partners.
Phreesia (PHR) Slid on Guidance Cut
Phreesia (PHR) experienced a stock slide after its management reduced its fiscal 2027 revenue outlook due to uncertain pharmaceutical spending, despite strong execution and improved profitability. Conestoga Capital Advisors, holding PHR in its Q1 2026 portfolio, noted the guidance cut overshadowed otherwise positive performance. The article also mentions increased hedge fund interest in Phreesia but suggests other AI stocks might offer better potential.
Phreesia (PHR) Slid on Guidance Cut
Phreesia, Inc. (PHR) experienced a stock slide after management lowered its fiscal 2027 outlook, despite strong execution and a 16% revenue increase. Conestoga Capital Advisors, an asset management company, noted this reduction in forward revenue expectations as the primary concern overshadowing Phreesia's otherwise positive performance. The company's market capitalization stands at $597.3 million, and its shares have seen a significant decline over the past 52 weeks.
Phreesia, Inc. (PHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Phreesia, Inc. (PHR) following a 26.5% stock drop on March 31, 2026. This decline occurred after Phreesia announced a lowered revenue outlook for fiscal 2027. The law firm is encouraging investors who purchased Phreesia securities to contact them to learn more about potential claims and to assist in the investigation.
Phreesia (NYSE: PHR) extends receivables facility to 2029 and adds co-guaranty
Phreesia, Inc. has amended its receivables financing facility, increasing the limit from $200 million to $300 million and extending the termination date to April 30, 2029. This update also adds Phreesia as a joint and several co-guarantor for AccessOne MedCard's performance obligations. The changes aim to provide a longer-dated funding source supported by patient financing receivables.
Phreesia (NYSE: PHR) director takes stock units instead of cash retainer
Edward L. Cahill, a director at Phreesia, Inc. (NYSE: PHR), opted to receive 1,085 shares of common stock valued at $9.21 per share as deferred stock units, instead of a cash retainer. This decision was made under the company's Non-Employee Director Deferred Compensation Program. Following this grant, Cahill directly holds 65,613 shares of Phreesia common stock, with the underlying shares to be delivered upon his departure from the board or five years from the grant date.
Gillian Munson (NYSE: PHR) takes fees in 1,085 stock units
Phreesia director Gillian Munson received 1,085 deferred stock units valued at $9.21 each as compensation for her annual cash retainer. These units convert into common shares after she leaves the board or five years from the grant date, increasing her direct holdings to 46,814 shares. This transaction is considered a neutral event, reflecting a non-cash compensation method rather than a market purchase or sale.
Phreesia (PHR) director opts for 1,085 deferred stock units as fees
Phreesia director Lainie Goldstein reported receiving 1,085 deferred stock units (DSUs) as compensation for her services, rather than a cash retainer. These DSUs, valued at $9.21 per share, bring her total direct holdings to 51,195 shares. The stock units are part of Phreesia's Non-Employee Director Deferred Compensation Program and will convert to common stock 90 days after her separation from service.
Phreesia Expands Receivables Facility to $300 Million, Extends Maturity to 2029 With PNC
Phreesia has increased its receivables purchase facility to $300 million from $200 million and extended its maturity to April 30, 2029, through an amendment with PNC Bank and PNC Capital Markets. The company also became a joint and several co-guarantor under an Amended and Restated Performance Guaranty with PNC. These actions enhance Phreesia's liquidity and financial flexibility for general corporate needs.
